Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
207 hedge funds and large institutions have $3.08B invested in Immunomedics Inc in 2018 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 53 reducing their positions, and 26 closing their positions.
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
53% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 53
8% more funds holding
Funds holding: 192 → 207 (+15)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
11% less capital invested
Capital invested by funds: $3.48B → $3.08B (-$400M)
44% less call options, than puts
Call options by funds: $99.7M | Put options by funds: $177M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$90.5M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$24.3M |
| 3 |
BlackRock
New York
|
+$23.1M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$17.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$70.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$69.5M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$63.8M |
| 4 |
O
OrbiMed
New York
|
-$14.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.3M |
IMMU Hedge Fund Activity: Q3 2018 in Review
207 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q3 2018, worth a combined $3.08B — down 11% from $3.48B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IMMU positions and 26 closed out — a net gain of 15 holders — while 81 added to existing stakes and 53 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $90.5M. The largest seller was Millennium Management, cutting an estimated $70.8M.
- 207 institutional investors held Immunomedics Inc (IMMU) as of Q3 2018, up from 192 in Q2 2018.
- Funds reported $3.08B of Immunomedics Inc stock for Q3 2018, down 11% quarter-over-quarter.
- 41 funds opened new Immunomedics Inc positions in Q3 2018 and 26 closed out, a net change of +15 holders.
- The largest Immunomedics Inc buyer in Q3 2018 was T. Rowe Price Associates, an estimated $90.5M added.
- The largest Immunomedics Inc seller in Q3 2018 was Millennium Management, an estimated $70.8M sold.
Based on aggregated 13F filings for Q3 2018.